Mathilde Bahuaud1, Constance Beaudouin-Bazire2, Marine Husson1, Anna Molto2, Odile Launay3, Frédéric Batteux1, Maxime Dougados2. 1. a Plateforme d'Immunomonotoring Vaccinal, Laboratoire d'Immunologie , Groupe hospitalier Cochin-Broca-Hôtel Dieu, AP-HP , Paris , France. 2. b Service de Rhumatologie B , Groupe hospitalier Cochin-Broca-Hôtel Dieu, APHP , Paris , France. 3. c Centre d'Investigation Clinique Cochin-Pasteur (CIC1417) , Groupe hospitalier Cochin-Broca-Hôtel Dieu, AP-HP , Paris , France.
Abstract
OBJECTIVES: Patients with rheumatoid arthritis (RA) are at an increased risk of Pneumococcal infections. Immunogenicity and persistence of a prime-boost revaccination strategy using 13-valent/23-valent anti-pneumococcal vaccines was evaluated in patients with RA treated by Methotrexate (MTX) and anti-TNF. METHOD: Twenty-four patients with RA received one dose of PCV13 (Prevenar13®; Pfizer) followed two months later by one dose of PPV23 (Pneumovax®, Merck). Concentrations of IgG specific for 7 serotypes common to both vaccines and 3 uncommon serotypes, included only in the PPV23 were measured by ELISA and Opsonophagocytic Assay (OPA) at baseline and after 4, 12 and 24 months post-vaccine. RESULTS: Similar percentages of protection were found at 4 months (63% vs. 55%), 12 months (54% vs. 50%) and 24 months (52% vs. 55%) for the 7 common and 3 uncommon serotypes when antibody titers were assayed by ELISA. Based on functional antibody measurements by OPA, a decrease of protected patients was observed 24 months after vaccine with only 19% of patients protected compared to 29% at baseline. CONCLUSION: Although the combined pneumococcal revaccination strategy induces good protection in the short term in RA patients, this protection does not persist beyond two years with levels of functional antibody decreasing below pre-vaccine levels. We did not observe a higher efficacy of the conjugate vaccine compared to the polysaccharide vaccine. Our results clearly question the advantage of the prime-boost strategy as it highlight the possible hyporesponse induced by PPV23 against the immune response elicited by the primo-injection of the PCV13 vaccine.
OBJECTIVES:Patients with rheumatoid arthritis (RA) are at an increased risk of Pneumococcal infections. Immunogenicity and persistence of a prime-boost revaccination strategy using 13-valent/23-valent anti-pneumococcal vaccines was evaluated in patients with RA treated by Methotrexate (MTX) and anti-TNF. METHOD: Twenty-four patients with RA received one dose of PCV13 (Prevenar13®; Pfizer) followed two months later by one dose of PPV23 (Pneumovax®, Merck). Concentrations of IgG specific for 7 serotypes common to both vaccines and 3 uncommon serotypes, included only in the PPV23 were measured by ELISA and Opsonophagocytic Assay (OPA) at baseline and after 4, 12 and 24 months post-vaccine. RESULTS: Similar percentages of protection were found at 4 months (63% vs. 55%), 12 months (54% vs. 50%) and 24 months (52% vs. 55%) for the 7 common and 3 uncommon serotypes when antibody titers were assayed by ELISA. Based on functional antibody measurements by OPA, a decrease of protected patients was observed 24 months after vaccine with only 19% of patients protected compared to 29% at baseline. CONCLUSION: Although the combined pneumococcal revaccination strategy induces good protection in the short term in RApatients, this protection does not persist beyond two years with levels of functional antibody decreasing below pre-vaccine levels. We did not observe a higher efficacy of the conjugate vaccine compared to the polysaccharide vaccine. Our results clearly question the advantage of the prime-boost strategy as it highlight the possible hyporesponse induced by PPV23 against the immune response elicited by the primo-injection of the PCV13 vaccine.
Authors: Christine Juergens; Scott Patterson; James Trammel; David Greenberg; Noga Givon-Lavi; David Cooper; Alejandra Gurtman; William C Gruber; Daniel A Scott; Ron Dagan Journal: Clin Vaccine Immunol Date: 2014-07-02
Authors: M P M van der Linden; M R Batstra; L E Bakker-Jonges; J Detert; H Bastian; H U Scherer; R E M Toes; G-R Burmester; M D Mjaavatten; T K Kvien; T W J Huizinga; A H M van der Helm-van Mil Journal: Arthritis Rheum Date: 2011-05
Authors: Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori Journal: JAMA Date: 2006-05-17 Impact factor: 56.272
Authors: Nancy F Crum-Cianflone; Katherine Huppler Hullsiek; Mollie Roediger; Anuradha Ganesan; Sugat Patel; Michael L Landrum; Amy Weintrob; Brian K Agan; Sheila Medina; Jeremy Rahkola; Braden R Hale; Edward N Janoff Journal: J Infect Dis Date: 2010-10-01 Impact factor: 5.226
Authors: Hannah M Garcia Garrido; Albert Vollaard; Geert R D'Haens; Phyllis I Spuls; Frederike J Bemelman; Michael W Tanck; Godelieve J de Bree; Bob Meek; Martin P Grobusch; Abraham Goorhuis Journal: Vaccines (Basel) Date: 2022-05-17
Authors: Christien Rondaan; Victoria Furer; Marloes W Heijstek; Nancy Agmon-Levin; Marc Bijl; Ferdinand C Breedveld; Raffaele D'Amelio; Maxime Dougados; Meliha C Kapetanovic; Jacob M van Laar; Annette Ladefoged de Thurah; Robert Landewé; Anna Molto; Ulf Müller-Ladner; Karen Schreiber; Leo Smolar; Jim Walker; Klaus Warnatz; Nico M Wulffraat; Sander van Assen; Ori Elkayam Journal: RMD Open Date: 2019-09-09
Authors: Per Nived; Göran Jönsson; Bo Settergren; Jon Einarsson; Tor Olofsson; Charlotte Sværke Jørgensen; Lillemor Skattum; Meliha C Kapetanovic Journal: Arthritis Res Ther Date: 2020-02-22 Impact factor: 5.156
Authors: Marco Vincenzo Lenti; Caterina Mengoli; Marta Vernero; Nicola Aronico; Laura Conti; Federica Borrelli de Andreis; Sara Cococcia; Antonio Di Sabatino Journal: Front Immunol Date: 2020-03-23 Impact factor: 7.561